# AHOD2131 (COG / NCTN)

Source: https://nuclide.cc/trials/ahod2131/  
Nuclide record `ahod2131` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Asks whether early-stage Hodgkin lymphoma in children and adults can be treated with immunotherapy instead of some chemotherapy and radiation.

## Summary

AHOD2131, trial NCT05675410 run by the Children's Oncology Group and the NCI, asks whether early-stage classical Hodgkin lymphoma in children and adults aged 5 to 60 can be treated with brentuximab vedotin plus nivolumab in a response-adapted design, instead of some chemotherapy and radiation. It uses PET after two cycles to steer therapy, has progression-free survival as its primary endpoint, measures late effects, and is ongoing with no results yet. Nuclide links it to Hodgkin lymphoma, PET-adapted therapy, brentuximab vedotin, nivolumab, the Children's Oncology Group, Kara M. Kelly, the idea of chemotherapy-free early-stage Hodgkin treatment and the S1826 paper. Whether immunotherapy can spare young patients the late effects of chemotherapy and radiation without losing cures is the question it exists to answer.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-07
- Registry id: NCT05675410
- Phase: 3
- Setting: Newly diagnosed stage I-II classical Hodgkin lymphoma, age 5-60: standard therapy vs brentuximab vedotin + nivolumab (response-adapted), with or without radiation
- Sponsor: Children's Oncology Group / NCI

## Sources

- ClinicalTrials.gov NCT05675410: https://clinicaltrials.gov/study/NCT05675410

## Connected records

- technologies: [PET-adapted (response-adapted) therapy](https://nuclide.cc/technologies/pet-adapted-therapy/)

---
JSON: https://nuclide.cc/api/v1/entities/ahod2131.json